Oncolytics Biotech INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Anson Funds Management LP and affiliated entities have disclosed a 7% beneficial ownership stake in Oncolytics Biotech, Inc. through a Schedule 13G amendment.
NASDAQ
Anson Funds Management LP and its affiliates have reported a passive beneficial ownership of 9.6% in Oncolytics Biotech, Inc., totaling 8,185,743 shares.